Next 10 |
home / stock / mrvff / mrvff news
Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare (TSX:MRV; OTCQX:MRVFF) (“ Miravo ” or the “ Company ”) is pleased to announce that it has obtained a final court order from the Ontario Superior Court of Justice (Commercial List) approving its previously announ...
Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare (TSX:MRV; OTCQX:MRVFF) (“ Miravo ” or the “ Company ”) is pleased to announce that, at today’s special meeting of shareholders (the “ Meeting ”), its shareholders (“ Shareho...
Shareholders are reminded to vote their common shares prior to the proxy voting deadline of 9:00 a.m. (Toronto Time) on March 3, 2023 Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare (TSX:MRV; OTCQX:MRVFF) (“ Miravo ” or the “ Company ”) reminds it...
Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare (TSX:MRV; OTCQX:MRVFF) (“ Miravo ” or the “ Company ”) announced today that it has filed and is in the process of mailing the management information circular (the “ Circular ”) and related mate...
Canadian healthcare company Searchlight Pharma is set to acquire Nuvo Pharmaceuticals, doing business as Miravo Healthcare, ( OTCQX:MRVFF ) ( TSX: MRV:CA ). The two companies have entered into a definitive agreement for the acquisition of all of the issued and outstanding sha...
Miravo shareholders to receive $ 1.35 per common share in cash, reflecting a premium of 79.8% to the 90-day volume weighted average price per common share on the Toronto Stock Exchange for the period ended December 22, 2022 Agreement entered into after a thorough review of all alt...
Nuvo Pharmaceuticals Inc. (MRVFF) Q3 2022 Earnings Conference Call November 14, 2022 11:00 AM ET Company Participants Jesse Ledger – President and Chief Executive Officer Mary-Jane Burkett – Vice President and Chief Financial Officer Conference Ca...
The following slide deck was published by Nuvo Pharmaceuticals Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Nuvo Pharmaceuticals Inc. 2022 Q3 - Results - Earnings Call Presentation
Nuvo Pharmaceuticals press release ( OTCQX:MRVFF ): Q3 Revenue of $18.1M (+6.5% Y/Y). Net income of $0.4 million For further details see: Nuvo Pharmaceuticals reports Q3 results
- Blexten Canadian Prescriptions Increased 27% Quarter-Over-Prior Year Quarter- - Suvexx Canadian Prescriptions Increased 86% Quarter-Over- Prior Year Quarter – Miravo to Host Conference Call/Audio Webcast November 14th at 11:00 a.m. ET ...
News, Short Squeeze, Breakout and More Instantly...
Nuvo Pharmaceuticals Inc Company Name:
MRVFF Stock Symbol:
OTCMKTS Market:
Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare (TSX:MRV; OTCQX:MRVFF) (“ Miravo ” or the “ Company ”) is pleased to announce that it has obtained a final court order from the Ontario Superior Court of Justice (Commercial List) approving its previously announ...
Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare (TSX:MRV; OTCQX:MRVFF) (“ Miravo ” or the “ Company ”) is pleased to announce that, at today’s special meeting of shareholders (the “ Meeting ”), its shareholders (“ Shareho...
Shareholders are reminded to vote their common shares prior to the proxy voting deadline of 9:00 a.m. (Toronto Time) on March 3, 2023 Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare (TSX:MRV; OTCQX:MRVFF) (“ Miravo ” or the “ Company ”) reminds it...